1/1页9314: 跳转到查看:9357
发新话题 回复该主题
键盘左右键可以进行前后翻页操作
【有 0 人在聊天】 帮助

Bring That Pioneering Spirit Back! A 25-Year Perspective on the Vascular Stent

Bring That Pioneering Spirit Back! A 25-Year Perspective on the Vascular Stent

My personal perspective about intravascular stents has been for the most part very positive. From its humble beginnings in the late ‘70s the stent become a major therapeutic resource and has achieved worldwide application. However, some disappointments in the last few years dampened my early unbridled enthusiasm. In my view, during its third decade of life the stent evolution has been hampered by unfulfilled goals. I think this is related to a recent change in attitudes and perceptions by government, industry, the media, and people in general.
In regard to technological development, starting in the year 2000 the medical device industry has shown a pervasive reluctance to invest in new research and development. This has been a gradual change from the previous 15 years, when this industry invested boldly in new products, guided only by their instinct and everybody’s expectation that there should be a change in the status quo. Reviewing the circumstances of those days compared to the present, it is apparent that the differences where global and not just limited to biotechnology. The innovative spirit of the ‘80s was evident in the wondrous technological achievements that arose during this decade. The launching of the first space shuttle and the deployment of the first permanently manned space station left us in awe, although they did not affect us personally. Conversely, the advent of practical personal computers,compact discs, and cell phones did. The beginnings of the Internet were laid out by a burgeoning ARPANET and the introduction of the transmission control protocol-Internet protocol (TCP-IP) lead to the World Wide Web. In medicine and biology the development of PCR (polymerase chain reaction) made possible a great expansion in DNA and gene research. Closer to our specialty, it was during the ‘80s that all major innovations in endovascular treatments developed. Andreas Gruntzig, who had done the first coronary balloon angioplasties in Zurich in 1977, moved to Atlanta, Georgia, and started a program of clinical research and teaching with unprecedented success. Under his leadership and inspiration the balloon angioplasty catheter got rapidly refined and the new technique achieved massive acceptance. During those years laser, rotational, and, later, directional atherectomy and the rapid exchange balloon catheter appeared, and so did stents. Unquestionably, a new revolution in vascular therapy had started then, with lots of new technologies and applications of these technologies in very innovative ways. More
最后编辑黄珊 最后编辑于 2010-03-22 12:05:29

TOP

 

北京裕恒佳科技有限公司成立于2000年,坐落在北京中关村科技园丰台园 区。公司设计和开发具有创新技术的医疗器械,通过组合先进材料和精湛工艺,实现医疗器械的产业化。公司专注于血管腔内支撑型人工血管以及送放系统的研究、设计、生产和应用技术服务,在血管腔内支架人工血管的研制领域不断推出具有领先水平的系列产品,取得国家专利授权。公司获得医疗器械生产许可证和产品注册证,通过ISO9001质量体系认证,为北京市高新技术企业。
      公司始终把技术领先作为服务患者的最基本准则,为此公司提出以下3S1A技术概念,作为公司经营理念的基石。

TOP

 

文章太老,参考着看吧~

TOP

 
1/1页9314: 跳转到
发表新主题 回复该主题
首页   |    联系我们   |   加入我们    |    关于我们   |   友情链接    |   网站地图   |   企业邮箱